Showing 1 - 8 results of 8 for search 'Yanhong Gu', query time: 0.02s
Refine Results
-
1
-
2
-
3
Ti Coating-Enhanced Tribocatalytic Degradation of Organic Dyes by CdS Nanoparticles by Mingzhang Zhu, Jiannan Song, Senhua Ke, Yanhong Gu, Lina Bing, Zhenjiang Shen, Wanping Chen
Published 2025-02-01Get full text
Article -
4
Cholesterol biosynthesis induced by radiotherapy inhibits cGAS–STING activation and contributes to colorectal cancer treatment resistance by Lijun Zhu, Zhaohui Tang, Wen Jiang, Yuwen Dong, Xiaofei Li, Kai Huang, Tiancong Wu, Lingyan Xu, Wenjie Guo, Yanhong Gu
Published 2025-05-01Get full text
Article -
5
-
6
Author correction to “SHP2 inhibition triggers anti-tumor immunity and synergizes with PD-1 blockade” [Acta Pharm Sin B 9 (2019) 304–315] by Mingxia Zhao, Wenjie Guo, Yuanyuan Wu, Chenxi Yang, Liang Zhong, Guoliang Deng, Yuyu Zhu, Wen Liu, Yanhong Gu, Yin Lu, Lingdong Kong, Xiangbao Meng, Qiang Xu, Yang Sun
Published 2025-05-01Get full text
Article -
7
PD-1 antibody camrelizumab plus apatinib and SOX as first-line treatment in patients with AFP-producing gastric or gastro-esophageal junction adenocarcinoma (CAP 06): a multi-cente... by Yakun Wang, Jialin Lu, Xiaoyi Chong, Chang Wang, Xiaofeng Chen, Zhi Peng, Yanhong Gu, Yizhuo Wang, Xicheng Wang, Jian Li, Jifang Gong, Changsong Qi, Jiajia Yuan, Zhihao Lu, Ming Lu, Jun Zhou, Yanshuo Cao, Yang Chen, Cheng Zhang, Zhiguo Hou, Hongyi Kou, Lin Shen, Xiaotian Zhang
Published 2025-03-01Get full text
Article -
8
Camrelizumab plus gemcitabine and oxaliplatin (GEMOX) in patients with advanced biliary tract cancer: a single-arm, open-label, phase II trial by Jian Wang, Hao Wu, Jing Sun, Xiao Li, Yongqian Shu, Xiaofeng Wu, Guoqiang Wang, Huajun Li, Xiaofeng Chen, Yanhong Gu, Yang Shao, Qianwen Shao, Feipeng Zhu, Xiaofeng Qian, Jun Hu, Fengjiao Zhao, Weidong Mao, Gaohua Han, Changxian Li, Yongxiang Xia, Poshita Kumari Seesaha, Dongqin Zhu, Junling Zhang, Xuehao Wang, Xiangcheng Li
Published 2020-10-01Get full text
Article